Improving cancer treatment through advanced analysis of tumor markers
Statistical Methods For Quantitative Immunohistochemistry Biomarkers
This study is looking to improve breast cancer treatment by finding new ways to analyze tissue samples, which could help doctors better understand how different patients might respond to specific therapies, leading to more personalized and effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10559505 on NIH RePORTER |
What this research studies
This research focuses on enhancing the classification and management of breast cancer by developing new statistical methods for analyzing immunohistochemistry (IHC) biomarkers. By utilizing quantitative immunofluorescence (QIF) and tissue microarrays, the project aims to identify and validate new prognostic biomarkers that can predict patient responses to specific cancer therapies. The approach involves analyzing protein expression levels at the cellular level, which can provide deeper insights into tumor heterogeneity and improve treatment strategies. Patients may benefit from more personalized and effective treatment options based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer who are undergoing treatment or are part of clinical trials.
Not a fit: Patients with non-breast cancers or those not undergoing any form of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate prognostic tools and targeted therapies for breast cancer patients.
How similar studies have performed: Previous research has shown success in using similar quantitative methods for biomarker discovery in cancer, indicating a promising avenue for this project.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Chervoneva, Inna — Thomas Jefferson University
- Study coordinator: Chervoneva, Inna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.